4QG Stock Overview
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PCI Biotech Holding ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.13 |
| 52 Week High | kr0.23 |
| 52 Week Low | kr0.091 |
| Beta | 1.61 |
| 1 Month Change | 4.55% |
| 3 Month Change | -27.67% |
| 1 Year Change | -15.39% |
| 3 Year Change | -93.95% |
| 5 Year Change | n/a |
| Change since IPO | -91.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4QG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | -1.5% |
| 1Y | -15.4% | -19.9% | 0.9% |
Return vs Industry: 4QG exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 4QG underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| 4QG volatility | |
|---|---|
| 4QG Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4QG's share price has been volatile over the past 3 months.
Volatility Over Time: 4QG's weekly volatility has decreased from 20% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 7 | Ronny Skuggedal | www.pcibiotech.com |
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin.
PCI Biotech Holding ASA Fundamentals Summary
| 4QG fundamental statistics | |
|---|---|
| Market cap | €5.23m |
| Earnings (TTM) | -€1.73m |
| Revenue (TTM) | €254.10k |
20.6x
P/S Ratio-3.0x
P/E RatioIs 4QG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4QG income statement (TTM) | |
|---|---|
| Revenue | kr2.99m |
| Cost of Revenue | kr0 |
| Gross Profit | kr2.99m |
| Other Expenses | kr23.31m |
| Earnings | -kr20.31m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 100.00% |
| Net Profit Margin | -679.43% |
| Debt/Equity Ratio | 0% |
How did 4QG perform over the long term?
See historical performance and comparison